title: Influence of leukotrienes on in vitro growth of human mammary carcinoma cell line MCF-7.
abstract: OBJECTIVE
  The aim of this work was to study the action of leukotrienes on the growth of human mammary cancer cells MCF-7.
  
  
  METHODS
  The growth of the cells was measured by incorporation of 3H-thymidine. The action of leukotriene (LT)B4, LTD4, LTC4, LTE4 or arachidonate (AA) was tested in human mammary cancer cells MCF-7 in vitro.
  
  
  RESULTS
  LTB4 or LTD4 but not LTC4 or LTE4 reduced significant incorporation of 3H-thymidine in MCF-7 cells up to 52% or 56% respectively, when administered in concentrations 0.1-1000 pM. Agents in concentrations of 0.01 pM or 10000 pM did not effect 3H-thymidine incorporation. We have shown, that MCF-7 cells synthesise LTB4 when treated with calcium ionophor A23187 (10 microM). Leukotriene-antagonist LY171883 (10 microM) lifts inhibitory effects of LTB4 or LTD4. Arachidonic acid (10 microM) inhibits 3H-thymidine incorporation up to 72%. 5-lipoxygenase inhibitor MK-886 (100 nM) lifts the inhibitory effect of arachidonate.
  
  
  CONCLUSIONS
  LTB4 or LTD4 inhibits MCF-7 breast cancer cell growth. LT-receptors mediate the growth-inhibitory effect of LTB4 or LTD4.
authors.affiliation: Department of Obstetrics and Gynaecology, University of Heidelberg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Przylipiak
authors.forename: J
authors.initials: J
authors.lastname: Hafner
authors.forename: J
authors.initials: J
authors.lastname: Przylipiak
authors.forename: B
authors.initials: B
authors.lastname: Runnebaum
authors.forename: T
authors.initials: T
authors.lastname: Rabe
authors.forename: F M
authors.initials: FM
authors.lastname: Köhn
mesh_terms: D000098:Acetophenones / Q000494:pharmacology; D016718:Arachidonic Acid / Q000494:pharmacology; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D000001:Calcimycin / Q000494:pharmacology; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D020024:Leukotriene Antagonists; D007975:Leukotriene B4 / Q000494:pharmacology; D017998:Leukotriene D4 / Q000494:pharmacology; D015289:Leukotrienes / Q000494:pharmacology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009994:Osmolar Concentration; D013777:Tetrazoles / Q000494:pharmacology; D013936:Thymidine / Q000032:analysis / Q000378:metabolism; D014316:Tritium; D014407:Tumor Cells, Cultured; D002722:Chlorobenzenes
chemical_list: D000098:Acetophenones; D016718:Arachidonic Acid; D000001:Calcimycin; D007211:Indoles; D007476:Ionophores; D020024:Leukotriene Antagonists; D007975:Leukotriene B4; D017998:Leukotriene D4; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D013777:Tetrazoles; D013936:Thymidine; D014316:Tritium; C060893:MK-886; D002722:Chlorobenzenes; C044660:LY 171883